Cannabis Hyperemesis Syndrome Clinical Trial
Official title:
Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome
The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.
Patients presenting to the Emergency Department with nausea, vomiting and/or abdominal pain with a significant history of cannabis use and symptoms in a cyclic pattern will be assessed for study inclusion. After given written informed consent, patients will be treated with droperidol and diphenhydramine and symptoms will be assessed using a visual analog scale at time intervals up to 120 minutes. Patient will then be contacted at 24 and 48 hour intervals to assess symptoms on the same scale. This is a multicenter, prospective interventional study with results compared to a historical cohort using haloperidol. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04176055 -
Treatment Strategies in CHS
|
Phase 4 |